Summary
The utility of the VZV skin test in detecting individual susceptibility to varicella and zoster was determined. Its specificity particularly with regard to herpes simplex was also established.
The VZV skin test was negative or weakly positive during the early stage of herpes zoster, and strongly positive during recovery from that disease. A small-scale clinical trial to immunize elderly individuals has been performed for the purpose of preventing herpes zoster, and, perhaps, severe post-herpetic neuralgia as well. Sixty individuals ≥50 years old were screened for VZV antibodies by IAHA test and were given a VZV skin test for cell-mediated immunity. All were seropositive, but eight were skin-test negative. Thirty-seven individuals including the eight with negative skin tests were immunized with one dose of varicella vaccine (3.0 x 104 PFU/dose). After 5-7 weeks, the skin test reaction showed increased positivity, with a change in score from (—) to (+, ++) in 7/8 subjects, from (+) to (++, +++) in 3/5 subjects, and from (++) to (+++) in 6/10 subjects. Enhancement of the VZV antibody titer (defined as twofold or greater) was observed in all 15 vaccine recipients with a prevaccination titer of ≤1:16, and in 19 of 24 subjects with a prevaccination titer of ≥1:32.
These results indicate that giving live varicella vaccine with a high viral titer can induce a good boost immunity particularly cell-mediated immunity to VZV in the elderly.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Asano Y, Shiraki K, Takahashi M, Nagai H, Ozaki T, Yazaki T (1981) Soluble skin test antigen of varicella-zoster virus prepared from the fluid of infected cultures. J Infect Dis 143: 684–692
Baba K, Yabuuchi H, Okuni H, Takahashi M (1978) Studies with live varicella vaccine and inactivated skin test antigen: protective effect of the vaccine and clinical application of the skin test. Pediatrics 61: 550–555
Baba K, Shiraki K, Kanesaki T, Yamanishi K, Ogra PL, Yabuuchi H, Takahashi M (1987) Specificity of skin test with varicella-zoster virus antigen in varicella-zoster and herpes simplex virus infections. J Clin Microbiol 25: 2193–2196
Berger R, Luescher D, Just M (1984) Enhancement of varicella-zoster-specific immune responses in the elderly by boosting with varicella vaccine. J Infect Dis 149: 647
Berger R, Trannoy E, Hollander G, Bailleux F, Rudin C, Creusvaux H (1998) A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older. J Infect Dis 178 [Suppl 1]: 99–103
Chilmonczyk BA, Levin MJ, McDuffy R, Hayward AR (1985) Characterization of the human newborn response to herpesvirus antigen. J Immunol 134: 4184–4188
Florman AL, Umland ET, Ballow D, Cushing A, McLaren LC, Gribble TJ, Duncan MH (1985) Evaluation of a skin test for chickenpox. Infect Control 6: 314–316
Hayward AR, Herberger M (1987) Lymphocyte responses to varicella-zoster virus in the elderly. J Clin Immunol 7: 174–178
Hayward AR, Zebre GO, Levin MJ (1994) Clinical application of responder cell frequency estimates with four years of follow up. J Immunol Methods 170: 27–36
Kamiya H, Ihara T, Hattori A, Iwasa T, Sakurai M, Izawa T, Yamada A, Takahashi M (1977) Diagnostic skin test reactions with varicella virus antigen and clinical application of the test. J Infect Dis 136: 784–788
LaRussa P, Steinberg SP, Seeman MD, Gershon AA (1985) Determination of immunity of varicella-zoster virus by means of an intradermal skin test. J Infect Dis 152: 869–875
Levin MJ, Barber D, Goldblatt E, Jones M, LaFleur B, Chan C, Stinson D, Zerbe GO, Hayward AR (1998) Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect. J Infect Dis 178 [Suppl 1]: S109–112
Shiraki K, Takahashi M (1982) Virus particles and glycoprotein excreted from cultured cells infected with varicella-zoster virus (VZV). J Gen Virol 61: 271–275
Shiraki K, Yamanishi K, Takahashi M, Dohi Y (1984) Delayed-type hypersensitivity and in vitro lymphocyte response in guinea pigs immunized with a live varicella vaccine. Biken J 27: 19–22
Shiraki K, Yamanishi K, Takahashi M (1984) Biologic and-immunologic characterization of the soluble skin-test antigen of varicella-zoster virus. J Infect Dis 149: 501–504
Takahashi M, Baba K (1984) A live varicella vaccine: its protective effect and immunological aspects of varicella-zoster virus infection. In: De la Maza LM, Peterson E (eds) Medical virology III. Elsevier Biomedical, New York, pp 255–278
Tanaka Y, Harino S, Danjo S, Hara J, Yamanishi K, Takahashi M (1984) Skin test with varicella-zoster virus antigen for ophthalmic herpes zoster. Am J Ophthalmol 98: 7–10
Torinuki W (1991) Delayed type hypersensitivity skin reaction to both varicella-zoster virus antigen and tuberculin PPD in patients with herpes zoster. Clin Dermatol 6: 381–384 [in Japanese]
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer-Verlag Wien
About this paper
Cite this paper
Takahashi, M. et al. (2001). Immunization of the elderly to boost immunity against varicella-zoster virus (VZV) as assessed by VZV skin test reaction. In: Gershon, A.A., Arvin, A.M., Calisher, C.H. (eds) Immunity to and Prevention of Herpes Zoster. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6259-0_17
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6259-0_17
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-83555-5
Online ISBN: 978-3-7091-6259-0
eBook Packages: Springer Book Archive